Learn more about Peter Attia’s digital program
#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation
“If you learn nothing else today, the first thing is, lipids, for the most part, go nowhere in the human body unless they’re a passenger inside a lipoprotein.” –Tom Dayspring
#20 – Tom Dayspring, M.D., FACP, FNLA – Part I of V: an introduction to lipidology
“Illustrating things made me understand . . . I just learned by illustrating.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
#19 – Dave Feldman: stress testing the lipid energy model
“I am on a journey of science, not of advocacy: I’m going to be quite a skeptic.” —Dave Feldman
Transcript — The Drive — Dave Feldman
Transcript of episode 19 of The Drive with Peter Attia, released October 8, 2018.
Statins, Lp(a), and upcoming podcast guests
In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.
#18 – Richard Isaacson, M.D.: Alzheimer’s prevention
“Anyone with a brain is at risk for Alzheimer’s.” —Richard Isaacson
AMA, Alzheimer’s, podcast rec, and NAD rec
Spoiler alert: Not sure taking NAD precursors orally is doing much beyond enriching the companies that make them.
Alzheimer’s prevention and the most important thing
So ironically, while Marks applies these insights to financial investments, many of the same principles apply to the way we should treat our health.
#14 – Robert Lustig, M.D., M.S.L.: fructose, processed food, NAFLD, and changing the food system
“Neurons like to be tickled, not bludgeoned.” —Rob Lustig